Dataset opportunity
Isa Pharma — 医疗影像数据集机会
Isa Pharma 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
67.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场预计将从 2024 年的 17.0 亿美元增长到 2034 年的 168.8 亿美元，复合年增长率为 25.8%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📝Published article
详细说明临床和免疫学结果的科学出版物
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
医疗人工智能与诊断影像公司
Isa Pharma 持有的高度专业化的医疗影像数据集源自其临床试验，包含 CT 和 MRI 等影像模态。该数据集独特地丰富了相应的免疫学和基因组学数据、病历和监管文件，使其特别适合开发和验证复杂的诊断人工智能模型，尤其是在肿瘤学和免疫学领域。
全球医疗影像人工智能市场正在迅速扩张，预计将从 2024 年的 17.0 亿美元增长到 2034 年的168.8 亿美元，复合年增长率为 25.8%。虽然访问受 GDPR 和潜在的共享所有权协议的约束，但该多模态数据的稀有性和深度为旨在引领精准医疗和诊断人工智能领域的实体提供了显著的竞争优势，证明了协商访问的合理性。⚠ 尽职调查（有价值的数据，可协商访问）：临床试验数据受严格的医疗隐私法规（GDPR）约束；数据所有权可能在特定的联合开发项目中共享（例如，与 Regeneron）；高度专业化的免疫学和基因组学数据集需要专家解读。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Isa Pharma 拥有其免疫疗法临床试验中稀有、专有的数据集，将患者生物标志物和免疫系统反应与具体的治疗结果联系起来。这是医疗人工智能公司开发下一代诊断人工智能以预测患者对特定癌症疗法反应的关键资产。在一个预计年增长率超过 25% 的市场中，关于HPV16 阳性癌症的独特数据为肿瘤学中预测算法的训练和验证提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity90
主导的“病历”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求极高，这得益于医疗影像人工智能市场激烈的竞争，该市场预计将以 25.8% 的复合年增长率增长，从而产生了对独特、高质量训练数据的迫切需求。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据胃口信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — ISA Pharmaceuticals 是一家临床阶段的免疫疗法中小企业，开发癌症和病毒感染疗法；其产生的临床试验数据，包括医疗影像，是其核心业务的有价值副产品，使其成为理想目标。问题：Pitchbook 将该公司列为“已停业”，这与其他所有来源和近期新闻相矛盾，但应予以澄清。
- Deep Qualification90
⚠ 需要审查 — 目标是一家临床阶段的免疫疗法公司，其研发产生了一个非常有价值的数据集（影像、基因组、免疫学），但数据访问受到监管框架（GDPR）和与 Regeneron 复杂的合作历史的严重限制，后者最近结束了其主要资产的合作。[许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该公司持有来自 I 期和 II 期临床试验的结构化数据，详细说明了患者反应、安全性和有效性指标，这些对于训练人工智能预测肿瘤学治疗结果至关重要。
Industrial data
这代表了详细说明T 细胞反应和免疫系统激活的专有数据，提供了对理解免疫疗法疗效机制的人工智能模型至关重要的独特纵向视图。
Regulatory records
该数据集包括对试验参与者的深入分子和生物标志物表征，提供了开发和验证能够识别治疗反应者的人工智能算法所需的粒度、患者级别数据。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Isa Pharma Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging Market to reach US$ 16.88 Billion by 2034 from US$ 1.70 Billion in 2024, growing at a CAGR of 25.8% (source: Market.us). Investment score 67.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Venamed — 医疗影像数据集机会
View opportunity →工业Powerbee — 工业传感器数据集机会
View opportunity →工业Everactive — 工业传感器数据集机会
View opportunity →